Jake Van Naarden, Loxo@Lilly CEO
January 27, 2023 03:19 PM EST
R&D
Pharma

Lil­ly en­ters ripe BTK field with quick FDA nod in man­tle cell lym­phoma

Kyle LaHucik

Senior Reporter

Eli Lil­ly has suc­ceed­ed in its at­tempt to get the first non-co­va­lent ver­sion of Bru­ton’s ty­ro­sine ki­nase, or BTK, in­hibitors to mar­ket, push­ing it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times